Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

  • Equillium Inc EQ has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD).
  • The results were presented at the European Hematology Association 2021 Virtual Congress.
  • All patients in the study (N=20) were evaluated as high-risk aGVHD and achieved complete response (CR) and overall response rates (ORR) at Day 29 of 55% and 70%, respectively.
  • Responses observed were generally rapid – within 15 days – and durable through Day 29 and beyond.
  • 14 patients were characterized as treatment naïve – receiving itolizumab within three days of first steroid administration – and achieved CR and ORR of 64% and 71%, respectively.
  • Additionally, responding patients experienced clinically meaningful reductions in steroid administration.
  • Across all dosing cohorts, 60% of patients (12/20) reported serious adverse events, with only 10% (2/20) of these events reported as treatment-related. There were 4 (20%) adverse events that led to death, and none were treatment-related.
  • Overall survival at month six across all dosing cohorts was 67%.
  • The optimal dose range observed 0.8 to 1.6 mg/kg; no further dose escalation is anticipated.
  • Price Action: EQ shares are down 11.4% at $6.19 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareGeneralBriefsGVHDIntegrated Telecommunication ServicesTelecommunication Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!